A detailed history of First National Trust CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, First National Trust CO holds 60,247 shares of BMY stock, worth $3.42 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
60,247
Previous 66,282 9.11%
Holding current value
$3.42 Million
Previous $2.75 Million 13.26%
% of portfolio
0.12%
Previous 0.11%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$39.66 - $51.75 $239,348 - $312,311
-6,035 Reduced 9.11%
60,247 $3.12 Million
Q2 2024

Aug 02, 2024

SELL
$40.25 - $52.99 $1.09 Million - $1.43 Million
-27,057 Reduced 28.99%
66,282 $2.75 Million
Q1 2024

Apr 26, 2024

SELL
$47.98 - $54.4 $5.72 Million - $6.48 Million
-119,168 Reduced 56.08%
93,339 $5.06 Million
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $1.81 Million - $2.16 Million
-37,295 Reduced 14.93%
212,507 $10.9 Million
Q3 2023

Nov 06, 2023

SELL
$57.89 - $64.73 $3.93 Million - $4.39 Million
-67,816 Reduced 21.35%
249,802 $14.5 Million
Q2 2023

Aug 01, 2023

BUY
$63.71 - $70.74 $342,823 - $380,651
5,381 Added 1.72%
317,618 $20.3 Million
Q1 2023

Apr 26, 2023

BUY
$65.71 - $74.53 $148,504 - $168,437
2,260 Added 0.73%
312,237 $21.6 Million
Q4 2022

Feb 02, 2023

BUY
$68.48 - $81.09 $526,063 - $622,933
7,682 Added 2.54%
309,977 $22.3 Million
Q3 2022

Nov 02, 2022

BUY
$0.13 - $76.84 $650 - $384,507
5,004 Added 1.68%
302,295 $21.5 Million
Q2 2022

Aug 03, 2022

BUY
$72.62 - $79.98 $5.53 Million - $6.09 Million
76,202 Added 34.47%
297,291 $22.9 Million
Q1 2022

May 03, 2022

BUY
$61.48 - $73.72 $2.32 Million - $2.78 Million
37,709 Added 20.56%
221,089 $16.1 Million
Q4 2021

Feb 03, 2022

BUY
$53.63 - $62.52 $609,290 - $710,289
11,361 Added 6.6%
183,380 $11.4 Million
Q3 2021

Nov 05, 2021

BUY
$59.17 - $69.31 $222,775 - $260,952
3,765 Added 2.24%
172,019 $10.2 Million
Q2 2021

Aug 06, 2021

SELL
$61.91 - $67.42 $206,346 - $224,710
-3,333 Reduced 1.94%
168,254 $11.2 Million
Q1 2021

May 06, 2021

SELL
$59.34 - $66.74 $793,909 - $892,914
-13,379 Reduced 7.23%
171,587 $10.8 Million
Q4 2020

Feb 10, 2021

BUY
$57.74 - $65.43 $1.16 Million - $1.32 Million
20,123 Added 12.21%
184,966 $11.5 Million
Q3 2020

Nov 04, 2020

BUY
$57.43 - $63.64 $558,047 - $618,389
9,717 Added 6.26%
164,843 $9.94 Million
Q2 2020

Aug 06, 2020

BUY
$54.82 - $64.09 $573,088 - $669,996
10,454 Added 7.23%
155,126 $9.12 Million
Q1 2020

Apr 29, 2020

BUY
$46.4 - $67.43 $344,195 - $500,195
7,418 Added 5.4%
144,672 $8.06 Million
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $285,713 - $372,687
5,806 Added 4.42%
137,254 $8.81 Million
Q3 2019

Nov 01, 2019

BUY
$42.77 - $50.71 $338,267 - $401,065
7,909 Added 6.4%
131,448 $6.67 Million
Q2 2019

Jul 22, 2019

BUY
$44.62 - $49.34 $1.59 Million - $1.75 Million
35,549 Added 40.4%
123,539 $5.6 Million
Q1 2019

Apr 25, 2019

BUY
$45.12 - $53.8 $1.57 Million - $1.88 Million
34,902 Added 65.74%
87,990 $4.2 Million
Q4 2018

Jan 28, 2019

SELL
$48.76 - $63.23 $182,362 - $236,480
-3,740 Reduced 6.58%
53,088 $2.76 Million
Q3 2018

Oct 31, 2018

SELL
$55.19 - $62.25 $219,380 - $247,443
-3,975 Reduced 6.54%
56,828 $0
Q2 2018

Jul 30, 2018

SELL
$50.53 - $62.98 $104,091 - $129,738
-2,060 Reduced 3.28%
60,803 $3.37 Million
Q1 2018

Apr 30, 2018

SELL
$59.92 - $68.98 $186,530 - $214,734
-3,113 Reduced 4.72%
62,863 $3.98 Million
Q4 2017

Jan 17, 2018

SELL
$59.94 - $65.35 $86,553 - $94,365
-1,444 Reduced 2.14%
65,976 $4.04 Million
Q3 2017

Nov 06, 2017

SELL
$55.23 - $63.74 $21,484 - $24,794
-389 Reduced 0.57%
67,420 $4.3 Million
Q2 2017

Aug 07, 2017

BUY
N/A
67,809
67,809 $3.78 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $121B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track First National Trust CO Portfolio

Follow First National Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First National Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on First National Trust CO with notifications on news.